Journal of Biomedical Engineering Research (대한의용생체공학회:의공학회지)

The Korean Society of Medical and Biological Engineering (대한의용생체공학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Reference of the Maximum Standardized Uptake Values to the Pancreatic Cancer, Pancreatitis and Normal Pancreas in the 18F-FDG PET-CT

18F-FDG PET-CT 검사에서 췌장암, 췌장염, 정상 췌장에 대한 최대 표준섭취계수의 임상적 기준 설정

  • Lee, Jae-Seung (Research institute of R&D Center, Segei Inspection Engineering Technology Co., Ltd.) ;
  • Kweon, Dae Cheol (Department of Radiological Science, College of Bioecological Health, Shinhan University)
  • 이재승 (세계아이티(주) 기업부설연구소) ;
  • 권대철 (신한대학교 바이오생태보건대학 방사선학과)
  • Received : 2018.01.22
  • Accepted : 2018.04.20
  • Published : 2018.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

The aim of this study were to establish the clinical references and guidelines for the maximum standardized uptake ($SUV_{max}$) value of pancreatic cancer, pancreatitis, and normal pancreas in $^{18}F-FDG$ PET-CT examinations for pancreatic disease. For this purpose, we performed the statistical analysis on the descriptive statistics, percentiles and inter quartiles range (IQR), normal distribution, and using the probability density function for pancreatic cancer, pancreatitis, and normal pancreas. As a result, the clinical reference of $SUV_{max}$ for the pancreatic cancer, pancreatitis, and normal pancreas was more than 3.45, 1.91 to 2.62, and less than 1.91, respectively. Also, optimal cut-off value for applying the dual time point PET-CT examination was determined to be 2.62. The results of this study are summarized as follows: first, we suggests the clinical reference and guideline for the pancreatic cancer, pancreatitis, and normal pancreas, and second, suggests a scientific approach to improve diagnostic accuracy of pancreatic disease by deviating from an approximate experience approach.

Keywords

References

  1. K.R. Zasadny, and R. L. Wahl, "Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D- glucose: variations with body weight and a method for correction," Radiology, vol. 189, no. 3, pp. 847-850, 1993. https://doi.org/10.1148/radiology.189.3.8234714
  2. G. Lucignani, G. Paganelli, and E. Bombardieri, "The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective," Nucl. Med. Commun,. vol. 25, no. 7, pp. 651-656, 2004. https://doi.org/10.1097/01.mnm.0000134329.30912.49
  3. M. S. Woo, C.I. Baek, J.U.Yoo, J.W. Song, I.C. Im, J.C. Son, S.D. Cho, and J.S. Lee, "Clinical correlation between the autoimmune thyroid disease for the thyroid autoimmune antibodies and the maximum standardized uptake value: base on the Hashimoto's thyroiditis and the Graves' disease," J. Korean Soc. Radiol., vol. 8, no. 5, pp. 240-248, 2014.
  4. K.A. Busing, S.O. Schonberg, J. Brade, and K. Wasser, "Impact of blood glucose, diabetes, insulin, and obesity on standardized uptake values in tumors and healthy organs on $^{18}F$-FDG PET/CT," Nucl. Med. Biol., vol. 40, no. 2, pp. 206- 213, 2013. https://doi.org/10.1016/j.nucmedbio.2012.10.014
  5. M.B. Ospina, J. Horton, J. Seida, B. Vandermeer, G. Liang, A.J. McEwan, and K. Gulenchyn, "Positron emission tomography for nine cancers (bladder, brain, cervical, kidney, ovarian, pancreatic, prostate, small cell lung, testicular)," Rockville M.D., Agency for Healthcare Research and Quality U.S., 2008.
  6. P. Berberat, H. Friess, M. Kashiwagi, H.G. Beger, and M.W. Buchler, "Diagnosis and staging of pancreatic cancer by positron emission tomography", World J. Surg., vol. 23, no. 9, pp. 882-887, 1999. https://doi.org/10.1007/s002689900593
  7. C.Y. Wong, J. Thie, K.J. Parling-Lynch, D. Zakalik, J.H. Margolis, M. Gaskill, J. Hill, F. Qing, D. Fink-Bennett, and C. Nagle, "Glucose-normalized standardized uptake value from (18)F-FDG PET in classifying lymphomas," J. Nucl. Med., vol. 46, no. 10, pp. 1659-1663, 2005.
  8. N. Dobert, C. Menzel, M. Diehl, N. Hamscho, K. Zaplatnikov, and F. Grunwald, "Increased FDG bone marrow uptake after intracoronary progenitor cell therapy," Nuklearmedizin, vol. 44, no. 1, pp. 15-19, 2005. https://doi.org/10.1055/s-0038-1623921
  9. Y. Kitasato, M. Yasunaga, K. Okuda, H. Kinoshita, H. Tanaka, Y. Okabe, A. Kawahara, M. Kage, H. Kaida, and M. Ishibashi, "Maximum standardized uptake value on $^{18}F$-fluoro- 2-deoxy-glucose positron emission tomography/computed tomography and glucose transporter-1 expression correlates with survival in invasive ductal carcinoma of the pancreas," Pancreas, vol. 43, no. 7, pp. 1060-1065, 2014. https://doi.org/10.1097/MPA.0000000000000185
  10. M. Yun, and B.I. Kim, "Roles of F-18 FDG PET or PET/CT for the evaluation of gastrointestinal malignancies," Korean J. Gastroenterol., vol. 48, no. 6, pp. 378-387, 2006.
  11. B.K. Goh, "Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness," Ann. Surg., vol. 243, no. 5, pp. 709-710l, 2006. https://doi.org/10.1097/01.sla.0000216766.93589.34
  12. A.J. Lemke, S.M. Niehues, N. Hosten, H. Amthauer, M. Boehmig, C. Stroszczynski, T. Rohlfing, S. Rosewicz, and R. Felix, "Retrospective digital image fusion of multidetector CT and $^{18}F$-FDG PET: clinical value in pancreatic lesions a prospective study with 104 patients," J. Nucl. Med., vol. 45, no. 8, pp. 1279-1286, 2004.
  13. C. Catalano, A. Laghi, F. Fraioli, F. Pediconi, A. Napoli, M. Danti, I. Reitano, and R. Passariello, "Pancreatic carcinoma: the role of high-resolution multislice spiral CT in the diagnosis and assessment of resectability," Eur. Radiol., vol. 13, no. 1, pp. 149-156, 2003. https://doi.org/10.1007/s00330-002-1473-4
  14. L.A. Orlando, S.L. Kulasingam, and D.B. Matchar, "Metaanalysis: the detection of pancreatic malignancy with positron emission tomography," Aliment. Pharmacol. Ther., vol. 20, no. 10, pp. 1063-1070, 2004. https://doi.org/10.1111/j.1365-2036.2004.02266.x
  15. R.J. Hyndman, and Y. Fan, "Sample quantiles in statistical packages," Am. Stat., vol. 50, no. 4, pp. 361-365, 1996.
  16. K.D. Min, and H.Y. Back, "Box-Cox power transformation using Minitab Macros," J. Korean Data Anal. Soc., vol. 12, no. 6, pp. 3339-3350, 2010.
  17. J.K. Kim, and E.H. Park, "Process capability analysis algorithm using Johnson Transformation," J. Korea Saf. Manag. Sci., vol. 20, no. 1, pp. 249-263, 2000.
  18. D. Delbeke, D.M. Rose, W.C. Chapman, C.W. Pinson, and J.K. Wright, "Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma," J. Nucl. Med., vol. 40, no. 4, pp. 1784-1791, 1999.
  19. B.S. Chang, and J.H. Kim, "Usefulness of scan position change on dual time point PET-CT in Pancreas cancer," J. Korean Soc. Radiol., vol. 10, no. 5, pp. 299-305, 2016. https://doi.org/10.7742/jksr.2016.10.5.299
  20. H. Zhuang, M. Pourdehnad, E.S. Lambright, A.J. Yamamoto, M. Lanuti, P. Li, P.D. Mozley, M.D. Rossman, S.D. Albelda, and A. Alavi, "Dual time point $^{18}F$-FDG PET imaging for differentiating malignant from inflammatory processes," J. Nucl. Med., vol. 42, no. 9, pp. 1412-1417, 2001.
  21. P. Berberat, H. Friess, M. Kashiwagi, H.G. Beger, and M.W. Buchler, "Diagnosis and staging of pancreatic cancer by positron emission tomography," World J. Surg., vol. 23, no. 9, pp. 882-887, 1999. https://doi.org/10.1007/s002689900593
  22. Y.D. Seo, S.M. Kim, K.H. Kim, and J.R. Kim, "$^{18}F$-FDG PET/CT for the preperative diagnosis of papillary thyroid microcarcinoma: the value of dual time point imaging," Nucl. Med. Mol. Imaging, vol. 43, no. 6, pp. 543-556, 2009.
  23. A. Danve, and J. O'Dell, "The role of $^{18}F$ Fluorodeoxyglucose positron emission tomography scanning in the diagnosis and management of systemic vasculitis," Int. J. Rheum. Dis., vol. 18, no. 7, pp. 714-724, 2015. https://doi.org/10.1111/1756-185X.12713